PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 7913199-8 1994 Parallel tests with beta-adrenergic antagonists revealed that the potentiation by isoproterenol could be significantly diminished by a single dose of the non-selective beta-adrenoreceptor blocking drug nadolol or the beta 2-selective antagonist ICI-118,551, but not the beta 1-selective antagonist metoprolol. Nadolol 202-209 hemoglobin, beta adult major chain Mus musculus 270-276 12959274-9 1993 6 A similar pattern to Raw was observed for both of the beta2-mediated metabolic responses which were also antagonised by nadolol. Nadolol 122-129 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 56-61 8255974-3 1993 They were pretreated with either placebo, 25 mg atenolol (a selective beta 1 antagonist), or 5, 20 and 80 mg nadolol (which blocks beta 1 and beta 2 but not beta 3-adrenoceptors). Nadolol 109-116 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 131-148 8255974-5 1993 Significant beta 2-blockade (from tremor data) occurred with 5 mg nadolol but not with 25 mg atenolol. Nadolol 66-73 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 12-18 8255974-7 1993 However, the rise in BMR was not totally blocked even by 80 mg nadolol (9.5%), which produced complete beta 1/beta 2 blockade, as evidenced by the elimination of the chronotropic effect of isoprenaline. Nadolol 63-70 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 103-116 8392210-5 1993 Nadolol 5 mg produced almost complete blunting of finger tremor (beta 2-blockade) whilst atenolol 25 mg had no significant effect. Nadolol 0-7 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 65-71 1504370-4 1992 Spleen cells from rats treated with nadolol, a peripherally acting beta-adrenergic receptor antagonist, and then shocked, showed dose-dependent attenuation of the suppression of interferon-gamma production. Nadolol 36-43 interferon gamma Rattus norvegicus 178-194 1877672-6 1991 Combined muscarinic-cholinergic (atropine; 0.11 mg/kg iv) and beta-adrenergic receptor blockade (nadolol; 0.5 mg/kg iv) abolished the stimulatory effects of ISO on subsidiary atrial and atrioventricular junctional pacemakers but did not affect the responses to VIP. Nadolol 97-104 vasoactive intestinal peptide Canis lupus familiaris 261-264 2380655-4 1990 Both sarcosine-isoleucine-angiotensin II ([Sar, Ile]-ANG II) and atropine blocked, and nadolol increased, the effect of EFS and exogenous angiotensin II on serotonin production. Nadolol 87-94 angiotensinogen Rattus norvegicus 138-152 2380655-5 1990 Nadolol blocked both the EFS-induced and the angiotensin II-induced production of melatonin. Nadolol 0-7 angiotensinogen Rattus norvegicus 45-59 33798116-0 2021 Stability of Extemporaneously Compounded Nadolol 10-mg/mL Suspension in Oral Mix in Glass and Plastic Bottles and Plastic Syringes. Nadolol 41-48 Mix paired-like homeobox Homo sapiens 77-80 33798116-2 2021 The objective of this study was to evaluate the stability of nadolol 10 mg/mL prepared in Oral Mix vehicle and stored in amber glass, amber polyethylene terephthalate, or amber polyvinyl chloride for 91 days at 4AEC and 25AEC; and polypropylene oral plastic syringes at 25AEC only. Nadolol 61-68 Mix paired-like homeobox Homo sapiens 95-98 33798116-3 2021 Three separate batches of nadolol suspension 10 mg/mL were prepared with Oral Mix. Nadolol 26-33 Mix paired-like homeobox Homo sapiens 78-81 33798116-8 2021 The concentration of nadolol 10 mg/mL in Oral Mix in all study samples from bottles and oral syringes remained within 3.5% of the initial concentration. Nadolol 21-28 Mix paired-like homeobox Homo sapiens 46-49 33798116-12 2021 On day 91, nadolol 10 mg/mL oral suspensions prepared with Oral Mix and stored in all bottle types at 4AEC will retain more than 98% of the initial concentration compared to 99% at 25AEC and only 94% when stored in oral syringes. Nadolol 11-18 Mix paired-like homeobox Homo sapiens 64-67 34303263-15 2021 Our data suggest that the reduced nadolol bioavailability is associated with the downregulation of ileal Oatp1a5 and Oct1 mRNA levels that subsequently lead to poor absorption of nadolol to the systemic circulation. Nadolol 34-41 solute carrier family 22 member 1 Rattus norvegicus 117-121 34303263-15 2021 Our data suggest that the reduced nadolol bioavailability is associated with the downregulation of ileal Oatp1a5 and Oct1 mRNA levels that subsequently lead to poor absorption of nadolol to the systemic circulation. Nadolol 179-186 solute carrier family 22 member 1 Rattus norvegicus 117-121 34425806-5 2021 The activity of beta-ARs was modulated by an agonist, norepinephrine (NE), and antagonists, including propranolol, atenolol, nebivolol, and nadolol. Nadolol 140-147 alanyl-tRNA synthetase 1 Homo sapiens 16-24 34425806-7 2021 Treatment of chondrocytes with IL-1beta and beta-blockers, including propranolol, atenolol, nebivolol, and nadolol, for 6 h significantly upregulated IL-1beta-induced expression of MMP-1, -3, and - 13, compared to chondrocytes treated with IL-1beta alone, indicating that antagonism of beta-AR confers catabolic signals. Nadolol 107-114 interleukin 1 alpha Homo sapiens 31-39 34425806-7 2021 Treatment of chondrocytes with IL-1beta and beta-blockers, including propranolol, atenolol, nebivolol, and nadolol, for 6 h significantly upregulated IL-1beta-induced expression of MMP-1, -3, and - 13, compared to chondrocytes treated with IL-1beta alone, indicating that antagonism of beta-AR confers catabolic signals. Nadolol 107-114 interleukin 1 alpha Homo sapiens 150-158 34425806-7 2021 Treatment of chondrocytes with IL-1beta and beta-blockers, including propranolol, atenolol, nebivolol, and nadolol, for 6 h significantly upregulated IL-1beta-induced expression of MMP-1, -3, and - 13, compared to chondrocytes treated with IL-1beta alone, indicating that antagonism of beta-AR confers catabolic signals. Nadolol 107-114 matrix metallopeptidase 1 Homo sapiens 181-200 34326250-8 2021 We exemplified our quantification method using beta1AR and demonstrated the allosteric effect of Nb80 binding in assisting displacement of nadolol to isoprenaline. Nadolol 139-146 adrenoceptor beta 1 Homo sapiens 47-54 34901807-1 2021 A novel frameshift mutation in the KCNH2 gene for long QT syndrome type 2 (LQTS2) was identified after torsades des pointes ventricular tachycardia in a 49-year-old patient managed with octreotide and nadolol for an acute variceal bleed. Nadolol 201-208 potassium voltage-gated channel subfamily H member 2 Homo sapiens 35-40 2663317-5 1989 With increasing nadolol doses, plasma norepinephrine concentration increased and isoproterenol sensitivity decreased in both young and elderly subjects, and creatinine clearance and plasma active renin levels were unchanged; plasma inactive renin levels increased in the young, and aldosterone concentration declined in the elderly with the lowest nadolol dose. Nadolol 16-23 renin Homo sapiens 241-246 2521058-4 1989 Thereafter, either pharmacologically inert, artificial CSF or nadolol was introduced through transcerebral, intraventricular perfusion with a significant reduction in aggression in the nadolol-treated animals when compared with those receiving artificial CSF. Nadolol 185-192 colony stimulating factor 2 Rattus norvegicus 55-58 2901435-5 1988 This result established that the dose ratio of cetamolol:atenolol:nadolol of 1.00:3.33:2.67 provides equipotent beta-1 blockade. Nadolol 66-73 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 112-118 2845445-6 1988 The behaviorally suppressive effects of either 0.4 mg/kg isoproterenol or 0.05 mg/kg clenbuterol were found to be completely antagonized by pretreatment with a 10.0 mg/kg dose of nadolol, a beta antagonist that does not penetrate the brain when administered systemically. Nadolol 179-186 amyloid beta precursor protein Rattus norvegicus 188-194 2875812-3 1986 Subjects randomly assigned to receive placebo, 50 mg bid atenolol, or 40 mg bid nadolol were tested before and after training both on and off drugs. Nadolol 80-87 BH3 interacting domain death agonist Homo sapiens 76-79 3038704-4 1986 Three months of nadolol therapy in migraine patients caused a significant increase in plasma ACTH and decrease in beta-EP concentrations. Nadolol 16-23 proopiomelanocortin Homo sapiens 93-97 3038704-4 1986 Three months of nadolol therapy in migraine patients caused a significant increase in plasma ACTH and decrease in beta-EP concentrations. Nadolol 16-23 proopiomelanocortin Homo sapiens 114-121 2869848-6 1986 However, using a multiple regression analysis there was a highly significant correlation between the combination of the pretreatment values of active renin, prorenin and aldosterone and the reduction in diastolic pressure with both nadolol (p less than 0.001) and metoprolol (p less than 0.003). Nadolol 232-239 renin Homo sapiens 150-155 2868577-1 1986 Isoprenaline, isoetharine, rimiterol, dobutamine and nadolol were investigated as substrates for purified pig-liver catechol-O-methyltransferase using a sensitive spectrophotometric assay. Nadolol 53-60 catechol-O-methyltransferase Sus scrofa 116-144 3905182-3 1985 Plasma concentrations of GIP tended to be higher during nadolol than placebo treatment. Nadolol 56-63 gastric inhibitory polypeptide Homo sapiens 25-28 2410671-0 1985 Effects of antihypertensive agents propranolol, metoprolol, nadolol, prazosin, and chlorthalidone on ACAT activity in rabbit and rat aortas and on LCAT activity in human plasma in vitro. Nadolol 60-67 sterol O-acyltransferase 1 Oryctolagus cuniculus 101-105 2858216-4 1985 Intravenous nadolol (0.05 and 0.75 mg/kg) reduced resting PAH and inulin clearances by up to 25%. Nadolol 12-19 phenylalanine hydroxylase Homo sapiens 58-61 6469432-4 1984 In the hypertensive population, nadolol was effective in lowering arterial pressure at rest, and significantly reduced the levels of SAP, DAP, MAP, HR and TTI reached at the end of the HG test. Nadolol 32-39 SH2 domain containing 1A Homo sapiens 133-136 6469432-4 1984 In the hypertensive population, nadolol was effective in lowering arterial pressure at rest, and significantly reduced the levels of SAP, DAP, MAP, HR and TTI reached at the end of the HG test. Nadolol 32-39 death associated protein Homo sapiens 138-141 6136140-3 1983 Since nadolol does not possess the membrane stabilising properties of propranolol, nor is it metabolized like propranolol, the effect on TBG concentration would appear to be due to beta-blockade. Nadolol 6-13 serpin family A member 7 Homo sapiens 137-140 6218831-0 1983 Inhibition of calmodulin-activated Ca2+-ATPase by propranolol and nadolol. Nadolol 66-73 calmodulin 1 Homo sapiens 14-24 6218831-5 1983 Nadolol, another beta-adrenergic blocker, is also an inhibitor of calmodulin-activated Ca2+-ATPase. Nadolol 0-7 calmodulin 1 Homo sapiens 66-76 6791883-1 1981 Nadolol, a new nonselective beta 1 and beta 2 adrenergic blocking agent, has a plasma half-life of 17 to 23 hours. Nadolol 0-7 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 28-45 33998-9 1979 Blood pressure response was independent of the pretreatment renin levels or the change in renin induced by nadolol; it was also independent of the changes in cardiac output and heart rate but was more pronounced in patients with milder baseline hypertension. Nadolol 107-114 renin Homo sapiens 90-95 37878-2 1979 2 The amount of nadolol excreted during the 120-h period after receiving the drug ranged from less than 1% in functionally anephric, patients up to 11.5% in patients with average creatinine clearance of 57.9 +/- 3.6 ml/min/1.73 m2. Nadolol 16-23 CD59 molecule (CD59 blood group) Homo sapiens 219-224 15737-6 1977 (3) Dose-related inhibition was observed with practolol, oxprenolol, timolol, nadolol, and atenolol at concentrations ranging from 10-8 to 10-5 m. Basal renin release was significantly (P is less than 0.01) inhibited by angiotensin II at 10-6 m, which also inhibited isoproterenol-stimulated renin release in a dose-related fashion. Nadolol 78-85 renin Rattus norvegicus 153-158 33387374-0 2021 Urinary Excretion of Nadolol as a Possible In Vivo Probe for Drug Interactions Involving P-glycoprotein. Nadolol 21-28 ATP binding cassette subfamily B member 1 Homo sapiens 89-103 33387374-2 2021 Previous studies have reported that nadolol is a substrate of P-glycoprotein, and the coadministration with itraconazole, a typical P-glycoprotein inhibitor, results in elevated plasma concentrations and cumulative urinary excretion of nadolol. Nadolol 36-43 ATP binding cassette subfamily B member 1 Homo sapiens 62-76 33387374-2 2021 Previous studies have reported that nadolol is a substrate of P-glycoprotein, and the coadministration with itraconazole, a typical P-glycoprotein inhibitor, results in elevated plasma concentrations and cumulative urinary excretion of nadolol. Nadolol 36-43 ATP binding cassette subfamily B member 1 Homo sapiens 132-146 33387374-2 2021 Previous studies have reported that nadolol is a substrate of P-glycoprotein, and the coadministration with itraconazole, a typical P-glycoprotein inhibitor, results in elevated plasma concentrations and cumulative urinary excretion of nadolol. Nadolol 236-243 ATP binding cassette subfamily B member 1 Homo sapiens 62-76 33387374-2 2021 Previous studies have reported that nadolol is a substrate of P-glycoprotein, and the coadministration with itraconazole, a typical P-glycoprotein inhibitor, results in elevated plasma concentrations and cumulative urinary excretion of nadolol. Nadolol 236-243 ATP binding cassette subfamily B member 1 Homo sapiens 132-146 33387374-3 2021 In this study, we assessed whether measurements of urinary-excreted nadolol can be an alternative method of plasma pharmacokinetics for P-glycoprotein-mediated drug interactions in humans. Nadolol 68-75 ATP binding cassette subfamily B member 1 Homo sapiens 136-150 33387374-7 2021 In the drug interactions of nadolol with itraconazole, rifampicin, a well-known P-glycoprotein inducer, or grapefruit juice, there were significant correlations between the differences in AUC0-48 and those in Ae, 0-48 from the controls in individual subjects. Nadolol 28-35 ATP binding cassette subfamily B member 1 Homo sapiens 80-94 33387374-8 2021 These results suggest that the measurements of urinary excretion of nadolol can be employed as a sensitive and reliable alternative to plasma pharmacokinetics for the evaluation of P-glycoprotein-mediated drug interactions. Nadolol 68-75 ATP binding cassette subfamily B member 1 Homo sapiens 181-195 33611903-17 2021 Nadolol succeeded in eliminating cardiac events in one patient with LQT2 post ineffective metoprolol medication. Nadolol 0-7 potassium voltage-gated channel subfamily H member 2 Homo sapiens 68-72 33506522-6 2021 The association was found statistically significant for nadolol [ROR (95% CI): 6.98 (5.40-9.03)], celiprolol [2.35 (1.35-4.10)], propranolol [2.14 (1.87-2.46)] and bisoprolol [1.42 (1.25-1.61)]. Nadolol 56-63 long intergenic non-protein coding RNA, regulator of reprogramming Homo sapiens 65-68 33381033-5 2020 In conclusion, nadolol was recommended as a relatively effective strategy for LQT2 in order to improve the prognosis of patients during a long follow-up period. Nadolol 15-22 potassium voltage-gated channel subfamily H member 2 Homo sapiens 78-82 33354416-10 2020 In addition, nadolol, a beta blocker, has also been identified in this study to bind to the EphB2-ephrinB2 complex, and the possibility of this drug treating multiple cancers is still relatively unexplored. Nadolol 13-20 amyloid beta precursor protein Homo sapiens 22-28 33354416-10 2020 In addition, nadolol, a beta blocker, has also been identified in this study to bind to the EphB2-ephrinB2 complex, and the possibility of this drug treating multiple cancers is still relatively unexplored. Nadolol 13-20 EPH receptor B2 Homo sapiens 92-97 33354416-10 2020 In addition, nadolol, a beta blocker, has also been identified in this study to bind to the EphB2-ephrinB2 complex, and the possibility of this drug treating multiple cancers is still relatively unexplored. Nadolol 13-20 ephrin B2 Homo sapiens 98-106 32518084-8 2020 An in vitro assay confirmed that NE down-regulates CCL2 production in both mouse and human macrophages, and that pre-treatment with the pan-beta-adrenergic receptor inhibitor nadolol rescues this activity. Nadolol 175-182 chemokine (C-C motif) ligand 2 Mus musculus 51-55 33304417-6 2020 This is the first report that demonstrates the efficacy and safety of trans-maternal administration of nadolol for treatment of symptomatic LQT2 fetuses with TdP. Nadolol 103-110 potassium voltage-gated channel subfamily H member 2 Homo sapiens 140-144 32595275-11 2020 Chronic beta-adrenergic receptor (beta-AR) blockade with nadolol abrogated stress-induced alterations in tumor burden and cleaved caspase-3 expression, lung MDSC frequency, and exosomal TGF-beta content. Nadolol 57-64 adrenergic receptor, beta 1 Mus musculus 34-41 32595275-11 2020 Chronic beta-adrenergic receptor (beta-AR) blockade with nadolol abrogated stress-induced alterations in tumor burden and cleaved caspase-3 expression, lung MDSC frequency, and exosomal TGF-beta content. Nadolol 57-64 caspase 3 Mus musculus 130-139 32595275-11 2020 Chronic beta-adrenergic receptor (beta-AR) blockade with nadolol abrogated stress-induced alterations in tumor burden and cleaved caspase-3 expression, lung MDSC frequency, and exosomal TGF-beta content. Nadolol 57-64 transforming growth factor alpha Mus musculus 186-194 32038628-8 2019 Furthermore, administering a beta1 + beta2-AR (nadolol), but not a beta1-AR (bisoprolol) antagonist prior to exercise abrogated the exercise-induced enhancement in TCR-gammadelta T-cell mobilization and ex vivo expansion. Nadolol 47-54 AA1 Homo sapiens 27-34 32038628-8 2019 Furthermore, administering a beta1 + beta2-AR (nadolol), but not a beta1-AR (bisoprolol) antagonist prior to exercise abrogated the exercise-induced enhancement in TCR-gammadelta T-cell mobilization and ex vivo expansion. Nadolol 47-54 adenosine A2a receptor Homo sapiens 37-45 30912151-0 2019 A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia. Nadolol 51-58 ryanodine receptor 2 Homo sapiens 20-24 30912151-1 2019 We report a 17-year-old boy with a large RYR2 exon 3 deletion who has a severe catecholaminergic polymorphic ventricular tachycardia (CPVT) phenotype characterized by refractoriness to both nadolol and flecainide which has previously not been reported in this subgroup of CPVT patients. Nadolol 190-197 ryanodine receptor 2 Homo sapiens 41-45 29480324-9 2018 EGCG competitively inhibited OATP1A2-mediated uptake of sulphobromophthalein and nadolol with Ki values of 21.6 and 19.4 muM, respectively. Nadolol 81-88 solute carrier organic anion transporter family member 1A2 Homo sapiens 29-36 29480324-9 2018 EGCG competitively inhibited OATP1A2-mediated uptake of sulphobromophthalein and nadolol with Ki values of 21.6 and 19.4 muM, respectively. Nadolol 81-88 latexin Homo sapiens 121-124 29210030-6 2018 Propranolol and nadolol block the beta-1 in the heart and the peripheral beta-2 adrenergic receptors. Nadolol 16-23 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 34-40 29210030-6 2018 Propranolol and nadolol block the beta-1 in the heart and the peripheral beta-2 adrenergic receptors. Nadolol 16-23 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 73-79 29059199-8 2017 Among the beta-blockers, nadolol showed a significant risk reduction in both LQT1 and LQT2 (HR 0.47 and 0.27, respectively), whereas atenolol and propranolol decreased the risk only in LQT1 (HR 0.36 and 0.46, respectively). Nadolol 25-32 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 77-81 29059199-8 2017 Among the beta-blockers, nadolol showed a significant risk reduction in both LQT1 and LQT2 (HR 0.47 and 0.27, respectively), whereas atenolol and propranolol decreased the risk only in LQT1 (HR 0.36 and 0.46, respectively). Nadolol 25-32 potassium voltage-gated channel subfamily H member 2 Homo sapiens 86-90 29059199-12 2017 Among them, nadolol was effective in LQT1 and LQT2, whereas other drugs showed different effectiveness depending on LQT genotype. Nadolol 12-19 potassium voltage-gated channel subfamily Q member 1 Homo sapiens 37-41 29059199-12 2017 Among them, nadolol was effective in LQT1 and LQT2, whereas other drugs showed different effectiveness depending on LQT genotype. Nadolol 12-19 potassium voltage-gated channel subfamily H member 2 Homo sapiens 46-50 27667324-0 2017 Nadolol reduces insulin sensitivity in liver cirrhosis: a randomized double-blind crossover trial. Nadolol 0-7 insulin Homo sapiens 16-23 27667324-8 2017 RESULTS: Compared with placebo, nadolol treatment reduced insulin sensitivity (79.7 +- 10.1 vs 99.6 +- 10.3 muL/kg fat-free mass min-1 (mU/L)-1 , P = .005). Nadolol 32-39 insulin Homo sapiens 58-65 27667324-8 2017 RESULTS: Compared with placebo, nadolol treatment reduced insulin sensitivity (79.7 +- 10.1 vs 99.6 +- 10.3 muL/kg fat-free mass min-1 (mU/L)-1 , P = .005). Nadolol 32-39 mitochondrial ubiquitin ligase activator of NFKB 1 Mus musculus 137-144 27667324-12 2017 CONCLUSIONS: Nadolol significantly worsened insulin sensitivity, glycemia, and disposition index in patients with liver cirrhosis. Nadolol 13-20 insulin Homo sapiens 44-51 27491078-4 2016 An individual with CPVT harboring a novel mutation in the type 2 cardiac ryanodine receptor (RyR2) was identified whose persistent ventricular arrhythmias during beta-blockade with nadolol were abolished during flecainide treatment. Nadolol 181-188 ryanodine receptor 2 Homo sapiens 93-97 26702643-0 2016 The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3. Nadolol 32-39 solute carrier family 22 member 1 Homo sapiens 58-62 26702643-0 2016 The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3. Nadolol 32-39 POU class 2 homeobox 2 Homo sapiens 64-68 26702643-0 2016 The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3. Nadolol 32-39 solute carrier family 47 member 1 Homo sapiens 70-75 26702643-0 2016 The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3. Nadolol 32-39 solute carrier family 47 member 2 Homo sapiens 77-84 26702643-0 2016 The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3. Nadolol 32-39 ATP binding cassette subfamily B member 1 Homo sapiens 90-104 26702643-0 2016 The Nonmetabolized beta-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3. Nadolol 32-39 solute carrier organic anion transporter family member 1B3 Homo sapiens 129-136 26702643-1 2016 Nadolol is a nonmetabolized beta-adrenoceptor antagonist and is a substrate of OATP1A2, but not of OATP2B1. Nadolol 0-7 solute carrier organic anion transporter family member 1A2 Homo sapiens 79-86 26702643-3 2016 We therefore investigated nadolol as a potential substrate of the hepatic uptake transporters OATP1B1, OATP1B3, and OCT1 and of the renal transporters OCT2, MATE1, and MATE2-K expressed in HEK cells. Nadolol 26-33 solute carrier organic anion transporter family member 1B1 Homo sapiens 94-101 26702643-3 2016 We therefore investigated nadolol as a potential substrate of the hepatic uptake transporters OATP1B1, OATP1B3, and OCT1 and of the renal transporters OCT2, MATE1, and MATE2-K expressed in HEK cells. Nadolol 26-33 solute carrier organic anion transporter family member 1B3 Homo sapiens 103-110 26702643-3 2016 We therefore investigated nadolol as a potential substrate of the hepatic uptake transporters OATP1B1, OATP1B3, and OCT1 and of the renal transporters OCT2, MATE1, and MATE2-K expressed in HEK cells. Nadolol 26-33 solute carrier family 22 member 1 Homo sapiens 116-120 26702643-4 2016 Moreover, the importance of P-glycoprotein (P-gp) for nadolol transport was studied using double transfected MDCK-OCT1-P-gp cells. Nadolol 54-61 ATP binding cassette subfamily B member 1 Homo sapiens 28-42 26702643-4 2016 Moreover, the importance of P-glycoprotein (P-gp) for nadolol transport was studied using double transfected MDCK-OCT1-P-gp cells. Nadolol 54-61 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 26702643-6 2016 In contrast, a significantly higher nadolol accumulation (at 1 and 10 muM) was found in OCT1, OCT2, MATE1, and MATE2-K cells compared to control cells (P < 0.01). Nadolol 36-43 solute carrier family 22 member 1 Homo sapiens 88-92 26702643-6 2016 In contrast, a significantly higher nadolol accumulation (at 1 and 10 muM) was found in OCT1, OCT2, MATE1, and MATE2-K cells compared to control cells (P < 0.01). Nadolol 36-43 POU class 2 homeobox 2 Homo sapiens 94-98 26702643-6 2016 In contrast, a significantly higher nadolol accumulation (at 1 and 10 muM) was found in OCT1, OCT2, MATE1, and MATE2-K cells compared to control cells (P < 0.01). Nadolol 36-43 solute carrier family 47 member 1 Homo sapiens 100-105 26702643-6 2016 In contrast, a significantly higher nadolol accumulation (at 1 and 10 muM) was found in OCT1, OCT2, MATE1, and MATE2-K cells compared to control cells (P < 0.01). Nadolol 36-43 solute carrier family 47 member 2 Homo sapiens 111-116 26702643-7 2016 Km values for OCT2-, MATE1-, and MATE2-K-mediated nadolol uptake were 122, 531, and 372 muM, respectively. Nadolol 50-57 POU class 2 homeobox 2 Homo sapiens 14-18 26702643-7 2016 Km values for OCT2-, MATE1-, and MATE2-K-mediated nadolol uptake were 122, 531, and 372 muM, respectively. Nadolol 50-57 solute carrier family 47 member 1 Homo sapiens 21-26 26702643-7 2016 Km values for OCT2-, MATE1-, and MATE2-K-mediated nadolol uptake were 122, 531, and 372 muM, respectively. Nadolol 50-57 solute carrier family 47 member 2 Homo sapiens 33-38 26702643-9 2016 The P-gp inhibitor zosuquidar significantly reduced basal to apical nadolol transport in monolayers of MDCK-OCT1-P-gp cells. Nadolol 68-75 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 26702643-9 2016 The P-gp inhibitor zosuquidar significantly reduced basal to apical nadolol transport in monolayers of MDCK-OCT1-P-gp cells. Nadolol 68-75 solute carrier family 22 member 1 Homo sapiens 108-112 26702643-9 2016 The P-gp inhibitor zosuquidar significantly reduced basal to apical nadolol transport in monolayers of MDCK-OCT1-P-gp cells. Nadolol 68-75 ATP binding cassette subfamily B member 1 Homo sapiens 113-117 26702643-10 2016 In summary, nadolol is a substrate of the cation transporters OCT1, OCT2, MATE1, MATE2-K, and of P-gp. Nadolol 12-19 solute carrier family 22 member 1 Homo sapiens 62-66 26702643-10 2016 In summary, nadolol is a substrate of the cation transporters OCT1, OCT2, MATE1, MATE2-K, and of P-gp. Nadolol 12-19 POU class 2 homeobox 2 Homo sapiens 68-72 26702643-10 2016 In summary, nadolol is a substrate of the cation transporters OCT1, OCT2, MATE1, MATE2-K, and of P-gp. Nadolol 12-19 solute carrier family 47 member 1 Homo sapiens 74-79 26702643-10 2016 In summary, nadolol is a substrate of the cation transporters OCT1, OCT2, MATE1, MATE2-K, and of P-gp. Nadolol 12-19 solute carrier family 47 member 2 Homo sapiens 81-88 26702643-10 2016 In summary, nadolol is a substrate of the cation transporters OCT1, OCT2, MATE1, MATE2-K, and of P-gp. Nadolol 12-19 ATP binding cassette subfamily B member 1 Homo sapiens 97-101 25257637-7 2014 In LQT1, the risk reduction for first cardiac events was similar among the 4 beta-blockers, but in LQT2, nadolol provided the only significant risk reduction (hazard ratio: 0.40 [0.16 to 0.98]). Nadolol 105-112 potassium voltage-gated channel subfamily H member 2 Homo sapiens 99-103 25257637-9 2014 CONCLUSIONS: Although the 4 beta-blockers are equally effective in reducing the risk of a first cardiac event in LQTS, their efficacy differed by genotype; nadolol was the only beta-blocker associated with a significant risk reduction in patients with LQT2. Nadolol 156-163 potassium voltage-gated channel subfamily H member 2 Homo sapiens 252-256 24419562-6 2014 [(3)H]-Nadolol uptake assays in human embryonic kidney 293 cells stably expressing the organic anion-transporting polypeptides OATP1A2 and OATP2B1 revealed that nadolol is a substrate of OATP1A2 (Michaelis constant (K(m)) = 84.3 mumol/l) but not of OATP2B1. Nadolol 161-168 solute carrier organic anion transporter family member 1A2 Homo sapiens 127-134 24419562-6 2014 [(3)H]-Nadolol uptake assays in human embryonic kidney 293 cells stably expressing the organic anion-transporting polypeptides OATP1A2 and OATP2B1 revealed that nadolol is a substrate of OATP1A2 (Michaelis constant (K(m)) = 84.3 mumol/l) but not of OATP2B1. Nadolol 161-168 solute carrier organic anion transporter family member 2B1 Homo sapiens 139-146 24419562-6 2014 [(3)H]-Nadolol uptake assays in human embryonic kidney 293 cells stably expressing the organic anion-transporting polypeptides OATP1A2 and OATP2B1 revealed that nadolol is a substrate of OATP1A2 (Michaelis constant (K(m)) = 84.3 mumol/l) but not of OATP2B1. Nadolol 161-168 solute carrier organic anion transporter family member 1A2 Homo sapiens 187-194 24419562-6 2014 [(3)H]-Nadolol uptake assays in human embryonic kidney 293 cells stably expressing the organic anion-transporting polypeptides OATP1A2 and OATP2B1 revealed that nadolol is a substrate of OATP1A2 (Michaelis constant (K(m)) = 84.3 mumol/l) but not of OATP2B1. Nadolol 161-168 solute carrier organic anion transporter family member 2B1 Homo sapiens 249-256 24419562-7 2014 Moreover, green tea significantly inhibited OATP1A2-mediated nadolol uptake (half-maximal inhibitory concentration, IC(50) = 1.36%). Nadolol 61-68 solute carrier organic anion transporter family member 1A2 Homo sapiens 44-51 24419562-8 2014 These results suggest that green tea reduces plasma concentrations of nadolol possibly in part by inhibition of OATP1A2-mediated uptake of nadolol in the intestine. Nadolol 70-77 solute carrier organic anion transporter family member 1A2 Homo sapiens 112-119 24419562-8 2014 These results suggest that green tea reduces plasma concentrations of nadolol possibly in part by inhibition of OATP1A2-mediated uptake of nadolol in the intestine. Nadolol 139-146 solute carrier organic anion transporter family member 1A2 Homo sapiens 112-119 24144049-6 2013 All experiments were performed in the presence of nadolol (a beta(1)/beta(2)-adrenoceptor antagonist). Nadolol 50-57 adrenoceptor beta 2 Homo sapiens 69-89 23473506-4 2013 3 cm teico-CSP resulted to be effective for the on-line pre-concentration, before the separation, of acebutolol, alprenolol, nadolol, oxprenolol and terbutaline with limit of detection at levels of few ng/mL. Nadolol 125-132 DnaJ heat shock protein family (Hsp40) member C5 Homo sapiens 11-14 23419354-1 2013 The aim of the present study was to clarify the involvement of P-glycoprotein (P-gp) or organic anion transporting polypeptide (Oatp) 1a5 in the pharmacokinetics of nadolol (NDL), a non-metabolized hydrophilic beta-adrenoceptor blocker, in rats. Nadolol 165-172 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 63-77 23419354-1 2013 The aim of the present study was to clarify the involvement of P-glycoprotein (P-gp) or organic anion transporting polypeptide (Oatp) 1a5 in the pharmacokinetics of nadolol (NDL), a non-metabolized hydrophilic beta-adrenoceptor blocker, in rats. Nadolol 165-172 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 79-83 23419354-2 2013 Pretreatment with itraconazole (ICZ, P-gp inhibitor, 50 mg/kg) for 30 min before oral administration of NDL (10 mg/kg) significantly increased the area under the plasma concentration-time curve (AUC0- )of NDL by 1.7-fold compared with control. Nadolol 104-107 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-41 23419354-2 2013 Pretreatment with itraconazole (ICZ, P-gp inhibitor, 50 mg/kg) for 30 min before oral administration of NDL (10 mg/kg) significantly increased the area under the plasma concentration-time curve (AUC0- )of NDL by 1.7-fold compared with control. Nadolol 205-208 ATP-binding cassette, subfamily B (MDR/TAP), member 1B Rattus norvegicus 37-41 22030895-0 2012 Nadolol block of Nav1.5 does not explain its efficacy in the long QT syndrome. Nadolol 0-7 sodium voltage-gated channel alpha subunit 5 Homo sapiens 17-23 21964666-12 2012 In Summary, the simultaneous administration of a glucocorticosteroid and a beta2-adrenoceptor inverse agonist was more effective at reducing indexes of airway inflammation than either drug given alone; suggesting nadolol may possess "glucocorticoid-sparing" properties. Nadolol 213-220 histocompatibility 2, O region beta locus Mus musculus 73-80 21871614-0 2011 beta1-adrenergic receptor up-regulation induced by nadolol is mediated via signal transduction pathway coupled to alpha1-adrenergic receptors. Nadolol 51-58 adrenergic receptor, beta 1 Mus musculus 0-25 21871614-2 2011 The present study attempted to clarify mechanisms of beta-AR up-regulation using mouse cerebral cortical neurons continuously exposed to nadolol (10 nM), a non-selective beta-AR antagonist, for 24 h. Nadolol dose-dependently induced both subtypes of beta-ARs, beta1- and beta2-ARs, which were not suppressed by protein A kinase inhibition with KT5720. Nadolol 137-144 adrenergic receptor, beta 1 Mus musculus 53-60 21871614-2 2011 The present study attempted to clarify mechanisms of beta-AR up-regulation using mouse cerebral cortical neurons continuously exposed to nadolol (10 nM), a non-selective beta-AR antagonist, for 24 h. Nadolol dose-dependently induced both subtypes of beta-ARs, beta1- and beta2-ARs, which were not suppressed by protein A kinase inhibition with KT5720. Nadolol 137-144 adrenergic receptor, beta 1 Mus musculus 260-280 21871614-2 2011 The present study attempted to clarify mechanisms of beta-AR up-regulation using mouse cerebral cortical neurons continuously exposed to nadolol (10 nM), a non-selective beta-AR antagonist, for 24 h. Nadolol dose-dependently induced both subtypes of beta-ARs, beta1- and beta2-ARs, which were not suppressed by protein A kinase inhibition with KT5720. Nadolol 200-207 adrenergic receptor, beta 1 Mus musculus 53-60 21871614-2 2011 The present study attempted to clarify mechanisms of beta-AR up-regulation using mouse cerebral cortical neurons continuously exposed to nadolol (10 nM), a non-selective beta-AR antagonist, for 24 h. Nadolol dose-dependently induced both subtypes of beta-ARs, beta1- and beta2-ARs, which were not suppressed by protein A kinase inhibition with KT5720. Nadolol 200-207 adrenergic receptor, beta 1 Mus musculus 170-177 21871614-2 2011 The present study attempted to clarify mechanisms of beta-AR up-regulation using mouse cerebral cortical neurons continuously exposed to nadolol (10 nM), a non-selective beta-AR antagonist, for 24 h. Nadolol dose-dependently induced both subtypes of beta-ARs, beta1- and beta2-ARs, which were not suppressed by protein A kinase inhibition with KT5720. Nadolol 200-207 adrenergic receptor, beta 1 Mus musculus 260-280 21871614-7 2011 These results indicate that the nadolol-induced beta1-AR up-regulation is mediated via PKC-relating pathway via alpha1-AR activation with stabilizing beta1-AR mRNA and that the increased expression of beta2-ARs is regulated by pathways different from those for beta1-AR expression. Nadolol 32-39 adrenergic receptor, beta 1 Mus musculus 48-56 21871614-7 2011 These results indicate that the nadolol-induced beta1-AR up-regulation is mediated via PKC-relating pathway via alpha1-AR activation with stabilizing beta1-AR mRNA and that the increased expression of beta2-ARs is regulated by pathways different from those for beta1-AR expression. Nadolol 32-39 adrenergic receptor, beta 1 Mus musculus 150-158 21871614-7 2011 These results indicate that the nadolol-induced beta1-AR up-regulation is mediated via PKC-relating pathway via alpha1-AR activation with stabilizing beta1-AR mRNA and that the increased expression of beta2-ARs is regulated by pathways different from those for beta1-AR expression. Nadolol 32-39 hemoglobin, beta adult minor chain Mus musculus 201-206 21871614-7 2011 These results indicate that the nadolol-induced beta1-AR up-regulation is mediated via PKC-relating pathway via alpha1-AR activation with stabilizing beta1-AR mRNA and that the increased expression of beta2-ARs is regulated by pathways different from those for beta1-AR expression. Nadolol 32-39 adrenergic receptor, beta 1 Mus musculus 150-158 21225244-0 2011 The effects of acute and chronic nadolol treatment on beta2AR signaling in HEK293 cells. Nadolol 33-40 adrenoceptor beta 2 Homo sapiens 54-61 21225244-4 2011 In this study, we examined the effects of nadolol on beta(2)AR levels and signaling components downstream of the beta(2)AR using a line of HEK293 cells expressing human beta(2)ARs. Nadolol 42-49 adrenoceptor beta 2 Homo sapiens 53-62 21225244-5 2011 Chronic treatment with NAD increased beta(2)AR protein levels and decreased receptor degradation, consistent with receptor stabilization by the inverse agonist. Nadolol 23-26 adrenoceptor beta 2 Homo sapiens 37-46 21225244-7 2011 A 5-min treatment with NAD decreased forskolin-stimulated phosphorylation at the beta(2)AR PKA site Ser 262 while a 24-h treatment with NAD increased it. Nadolol 23-26 adrenoceptor beta 2 Homo sapiens 81-90 21225244-10 2011 Chronic NAD treatment therefore increases cellular cAMP levels by mechanisms that include the upregulation of beta(2)AR and G(alpha)s. This effect may explain in part the beneficial effects of chronic nadolol treatment on airway contractility. Nadolol 8-11 adrenoceptor beta 2 Homo sapiens 110-119 21225244-10 2011 Chronic NAD treatment therefore increases cellular cAMP levels by mechanisms that include the upregulation of beta(2)AR and G(alpha)s. This effect may explain in part the beneficial effects of chronic nadolol treatment on airway contractility. Nadolol 201-208 adrenoceptor beta 2 Homo sapiens 110-119 20637193-5 2010 In both strains, relaxation to celiprolol was decreased in the presence of nadolol (a beta(1)/beta(2)-adrenoceptor antagonist, 10 microM). Nadolol 75-82 adrenoceptor beta 2 Rattus norvegicus 94-114 20369594-5 2010 The selective beta-3 adrenoceptor agonist BRL 37344 at high concentrations (10(-6) - 10(-5) M) produced a coronary vasodilator effect, but this effect was completely blocked by the beta-1/beta-2 adrenoceptor antagonist nadolol (10(-5) M). Nadolol 219-226 adrenergic receptor, beta 3 Mus musculus 14-33 20369594-5 2010 The selective beta-3 adrenoceptor agonist BRL 37344 at high concentrations (10(-6) - 10(-5) M) produced a coronary vasodilator effect, but this effect was completely blocked by the beta-1/beta-2 adrenoceptor antagonist nadolol (10(-5) M). Nadolol 219-226 hemoglobin, beta adult major chain Mus musculus 181-187 20369594-5 2010 The selective beta-3 adrenoceptor agonist BRL 37344 at high concentrations (10(-6) - 10(-5) M) produced a coronary vasodilator effect, but this effect was completely blocked by the beta-1/beta-2 adrenoceptor antagonist nadolol (10(-5) M). Nadolol 219-226 adrenergic receptor, beta 2 Mus musculus 188-207 19893132-3 2009 15 mg/kg of Nadolol (the dose sufficient to prevent CRH-induced increases in heart-rate for 2 hr), dissolved in saline was administered intraperitoneally, 30 minutes prior to CRH (The dose of interest for CRH - 1 mkg/kg - was determined earlier, as provoking the maximal increase of plasma corticosterone level after 20 minutes of its ICV injection). Nadolol 12-19 corticotropin releasing hormone Rattus norvegicus 52-55 19893132-7 2009 Thus, according our results, 30 min after injection, the dose of Nadolol, sufficient to prevent CRH-induced increase in heart rate, doesn"t preclude the CRH-induced increase of plasma corticosterone - one of key signs of the stress-axis activation. Nadolol 65-72 corticotropin releasing hormone Rattus norvegicus 96-99 19159673-7 2009 Similarly, pre-treatment of mice with the peripherally acting beta-adrenoceptor antagonist nadolol completely blocked the stress-induced increase in IL-10 and IL-19 mRNA expression. Nadolol 91-98 interleukin 10 Mus musculus 149-154 19159673-7 2009 Similarly, pre-treatment of mice with the peripherally acting beta-adrenoceptor antagonist nadolol completely blocked the stress-induced increase in IL-10 and IL-19 mRNA expression. Nadolol 91-98 interleukin 19 Mus musculus 159-164 17689526-8 2007 Consistent with a role for beta-adrenoceptor activation in the immunosuppressive actions of MDMA, pre-treatment with the beta-adrenoceptor antagonist nadolol blocked the MDMA-induced increase in IL-10, and also inhibited the suppressive action of MDMA on the innate IFN-gamma response. Nadolol 150-157 interleukin 10 Mus musculus 195-200 17689526-8 2007 Consistent with a role for beta-adrenoceptor activation in the immunosuppressive actions of MDMA, pre-treatment with the beta-adrenoceptor antagonist nadolol blocked the MDMA-induced increase in IL-10, and also inhibited the suppressive action of MDMA on the innate IFN-gamma response. Nadolol 150-157 interferon gamma Mus musculus 266-275 17622774-6 2007 Selective beta(3)-adrenoceptor agonist, BRL37344 ([4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid), caused biphasic relaxation which was not affected by nadolol (1 micromol/l). Nadolol 180-187 adrenoceptor beta 3 Rattus norvegicus 10-30 16920085-1 2006 Mechanisms of up-regulation of beta-adrenergic receptors (beta-ARs) induced by sustained exposure to 10(-8) M nadolol, a non-selective beta-AR antagonist, were examined using mouse cerebrocortical neurons. Nadolol 110-117 adrenergic receptor, beta 1 Mus musculus 58-65 16920085-8 2006 During 24 h after nadolol exposure, the increase in proteins of beta1- and beta2-ARs in the neuronal membrane was due to the increased receptor protein translocation from cytosol to membrane. Nadolol 18-25 hemoglobin, beta adult major chain Mus musculus 64-80 16135702-7 2005 Inhibition was abolished by the beta3-AR antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]ethyl]phenyl]benzenesulfonamide (L-748,337; 10(-6) M), but not by nadolol. Nadolol 185-192 adrenoceptor beta 3 Homo sapiens 32-40 15935613-12 2005 RU486 and nadolol treatment also tended to decrease IL-10, IFN-gamma, TNFalpha (nadolol only), and IL-1beta (RU486 only) in both exercise and control mice, suggesting that stress hormones may be necessary during infection for optimal responsiveness. Nadolol 10-17 interleukin 10 Mus musculus 52-57 15935613-12 2005 RU486 and nadolol treatment also tended to decrease IL-10, IFN-gamma, TNFalpha (nadolol only), and IL-1beta (RU486 only) in both exercise and control mice, suggesting that stress hormones may be necessary during infection for optimal responsiveness. Nadolol 10-17 interferon gamma Mus musculus 59-68 15935613-12 2005 RU486 and nadolol treatment also tended to decrease IL-10, IFN-gamma, TNFalpha (nadolol only), and IL-1beta (RU486 only) in both exercise and control mice, suggesting that stress hormones may be necessary during infection for optimal responsiveness. Nadolol 10-17 tumor necrosis factor Mus musculus 70-78 15935613-12 2005 RU486 and nadolol treatment also tended to decrease IL-10, IFN-gamma, TNFalpha (nadolol only), and IL-1beta (RU486 only) in both exercise and control mice, suggesting that stress hormones may be necessary during infection for optimal responsiveness. Nadolol 10-17 interleukin 1 beta Mus musculus 99-107 15652410-7 2005 Whilst pre-treatment with nadolol completely blocked the stress-induced increase in IL-10, it failed to alter the suppression of TNF-alpha or IL-1beta. Nadolol 26-33 interleukin 10 Rattus norvegicus 84-89 15595859-7 2004 Zonal displacement chromatography using CGP 12177A as the marker and racemic mixtures of the antagonists nadolol and propranolol demonstrated that the immobilized beta(2)-AR retained its ability to specifically bind these compounds. Nadolol 105-112 adrenoceptor beta 2 Homo sapiens 163-173 15145613-4 2004 Furthermore, MP inhibition of granzyme B mRNA was blocked by the beta-antagonist nadolol. Nadolol 81-88 granzyme B Homo sapiens 30-40 15069206-5 2004 In comparison with nontreated asthmatic mice, we observed that: (i) The beta-AR antagonists nadolol or carvedilol, given as a single i.v. Nadolol 92-99 adrenergic receptor, beta 1 Mus musculus 72-79 15069206-7 2004 (ii) Chronic treatment with nadolol or carvedilol significantly increased beta-AR densities in lung membranes by 719% and 828%, respectively. Nadolol 28-35 adrenergic receptor, beta 1 Mus musculus 74-81 12909312-10 2003 Pretreatment with nadolol, a beta(1)/beta(2)-AR blocker, blunted the rebound in peak tension elicited by beta(3)-AR agonists suggesting a non-specific action of these compounds on beta(1)- and beta(2)-AR. Nadolol 18-25 adrenergic receptor, beta 2 Mus musculus 37-47 12909312-10 2003 Pretreatment with nadolol, a beta(1)/beta(2)-AR blocker, blunted the rebound in peak tension elicited by beta(3)-AR agonists suggesting a non-specific action of these compounds on beta(1)- and beta(2)-AR. Nadolol 18-25 adrenergic receptor, beta 3 Mus musculus 105-115 12909312-10 2003 Pretreatment with nadolol, a beta(1)/beta(2)-AR blocker, blunted the rebound in peak tension elicited by beta(3)-AR agonists suggesting a non-specific action of these compounds on beta(1)- and beta(2)-AR. Nadolol 18-25 adrenergic receptor, beta 2 Mus musculus 193-203 12445584-9 2002 However, the ability of fenfluramine to suppress tumor necrosis factor-alpha production cannot be accounted for by increased interleukin-10 production, as pretreatment with the beta-adrenoceptor antagonist nadolol completely blocked the increase in interleukin-10 without altering the suppression of tumor necrosis factor-alpha induced by fenfluramine. Nadolol 206-213 tumor necrosis factor Rattus norvegicus 49-76 12445584-9 2002 However, the ability of fenfluramine to suppress tumor necrosis factor-alpha production cannot be accounted for by increased interleukin-10 production, as pretreatment with the beta-adrenoceptor antagonist nadolol completely blocked the increase in interleukin-10 without altering the suppression of tumor necrosis factor-alpha induced by fenfluramine. Nadolol 206-213 interleukin 10 Rattus norvegicus 249-263 12445584-9 2002 However, the ability of fenfluramine to suppress tumor necrosis factor-alpha production cannot be accounted for by increased interleukin-10 production, as pretreatment with the beta-adrenoceptor antagonist nadolol completely blocked the increase in interleukin-10 without altering the suppression of tumor necrosis factor-alpha induced by fenfluramine. Nadolol 206-213 tumor necrosis factor Rattus norvegicus 300-327 11908922-3 2002 We tested whether blocking SNS activity using 6-OHDA or the beta-receptor antagonist nadolol alters the typical pattern in production of T helper 1 (Th1) and Th2 cytokines seen in cultures of spleen cells from C57BL/6 mice infected with murine AIDS (MAIDS). Nadolol 85-92 heart and neural crest derivatives expressed 2 Mus musculus 158-161 11824942-4 2001 Furthermore, (+/-)-nadolol, which belongs to the aryloxypropanolamine class and has beta1- and beta2-adrenoceptor antagonistic characteristics, displays agonistic activity at beta3-adrenoceptors. Nadolol 13-26 beta-2 adrenergic receptor Cavia porcellus 84-113 11292254-7 2001 In nadolol-treated old mice, the frequency of the immature CD4-8- population was increased, and the intermediate CD4+8+ population was reduced. Nadolol 3-10 CD4 antigen Mus musculus 59-62 11292254-7 2001 In nadolol-treated old mice, the frequency of the immature CD4-8- population was increased, and the intermediate CD4+8+ population was reduced. Nadolol 3-10 CD4 antigen Mus musculus 113-116 11292254-10 2001 The percentage of CD8+44low naive cells in peripheral blood increased in nadolol-treated mice, suggesting that more CD4-8+ cells were exported from the thymus to the periphery. Nadolol 73-80 CD4 antigen Mus musculus 116-119 10808734-8 2000 Eleven patients (group VIII) received nadolol in a dose of 40-80 mg daily for two weeks. Nadolol 38-45 cytochrome c oxidase subunit 8A Homo sapiens 23-27 10644643-5 2000 Pretreatment of rats with the beta-adrenergic receptor antagonist nadolol also prevented OT-induced renin secretion. Nadolol 66-73 renin Rattus norvegicus 100-105 10644643-6 2000 Similarly, nadolol injected during infusion of OT markedly reduced the elevated plasma renin levels. Nadolol 11-18 renin Rattus norvegicus 87-92 10498836-7 1999 In the presence of nadolol, a beta1- and beta2-adrenoceptor antagonist, isoprenaline-induced relaxation persisted (Emax=55.6+/-5.3%), but occurred at higher concentrations (pD2=6.71+/-0.10) than in the absence of nadolol and lasted longer. Nadolol 19-26 adrenoceptor beta 2 Rattus norvegicus 41-59 10037693-10 1999 When the expression level of beta3-adrenoceptor was lowered, CFTR was not activated under base-line conditions but became sensitive to beta3-adrenoceptor stimulation (isoproterenol plus nadolol, SR 58611, or CGP 12177). Nadolol 186-193 adrenoceptor beta 3 Homo sapiens 29-47 10037693-10 1999 When the expression level of beta3-adrenoceptor was lowered, CFTR was not activated under base-line conditions but became sensitive to beta3-adrenoceptor stimulation (isoproterenol plus nadolol, SR 58611, or CGP 12177). Nadolol 186-193 CF transmembrane conductance regulator Homo sapiens 61-65 9878736-8 1999 The effect of IL-1beta on lung clearance was blocked by pretreatment with the beta-adrenergic antagonist, nadolol (0.5 mg/kg), but not by the alpha-antagonist phentolamine (5 mg/kg). Nadolol 106-113 interleukin 1 beta Rattus norvegicus 14-22 9299058-3 1997 Nadolol attenuated the 2-DG-induced suppression of splenic T-cell mitogenic response and interferon-gamma production and increased nitric oxide production by macrophages in a dose-dependent manner. Nadolol 0-7 interferon gamma Rattus norvegicus 89-105 9126981-6 1997 IgG2a inhibition was prevented by addition of the betaAR antagonist nadolol or exogenous IFN-gamma. Nadolol 68-75 immunoglobulin heavy variable V1-9 Mus musculus 0-5 8755668-4 1996 In the presence of nadolol, a beta1- and beta2-adrenoceptor antagonist, isoprenaline produced consistent negative inotropic effects. Nadolol 19-26 adrenoceptor beta 2 Homo sapiens 41-59 8738584-24 1996 Nadolol blocked the open field-induced rise in plasma IL-6 only when injected i.c.v. Nadolol 0-7 interleukin 6 Rattus norvegicus 54-58 8574280-7 1995 CONCLUSION: All three beta-adrenoceptor subtypes (beta 1, beta 2 and beta 3) may be involved in ephedrine-induced thermogenesis, but the resistance to complete inhibition by the non-selective antagonist nadolol indicates that at least 40% of the response is mediated by an atypical receptor, which is presumed to be the beta 3-adrenoceptor. Nadolol 203-210 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 50-56 8574280-7 1995 CONCLUSION: All three beta-adrenoceptor subtypes (beta 1, beta 2 and beta 3) may be involved in ephedrine-induced thermogenesis, but the resistance to complete inhibition by the non-selective antagonist nadolol indicates that at least 40% of the response is mediated by an atypical receptor, which is presumed to be the beta 3-adrenoceptor. Nadolol 203-210 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 58-75 7557820-12 1995 However, nadolol totally blunted the increase in insulin (15%) and free-fatty acids (4%) plasma levels. Nadolol 9-16 insulin Canis lupus familiaris 49-56 7981009-0 1994 The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Nadolol 53-60 adrenoceptor beta 1 Homo sapiens 73-99 7981009-2 1994 The aim of the present study was to evaluate the relative beta 1/beta 2 antagonist selectivity of the beta-adrenoceptor blocker nadolol, in lower than conventional clinical doses. Nadolol 128-135 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 58-64 7981009-2 1994 The aim of the present study was to evaluate the relative beta 1/beta 2 antagonist selectivity of the beta-adrenoceptor blocker nadolol, in lower than conventional clinical doses. Nadolol 128-135 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 65-71 7981009-8 1994 Nadolol produced dose-related reductions in exercise tachycardia in keeping with increasing beta 1-adrenoceptor blockade; mean % reduction (95% CI) compared with placebo: N5 10.7 (6.6 to 14.8), N20 21.4 (17.3 to 25.4), N80 38.9 (34.8 to 42.9). Nadolol 0-7 adrenoceptor beta 1 Homo sapiens 92-111 7981009-9 1994 However, even the lowest dose of nadolol (5 mg) produced almost complete blunting of beta 2-mediated effects and significantly increase exercise hyperkalaemia; peak exercise hyperkalaemia (mmol l-1) (means and 95% CI): PL 4.88 (4.68 to 5.07), N5 5.36 (5.17 to 5.55), N20 5.48 (5.28 to 5.67), N80 5.42 (5.22 to 5.61). Nadolol 33-40 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 85-91 7981009-10 1994 beta 2:beta 1 selectivity ratios significantly increased as the dose of nadolol was reduced. Nadolol 72-79 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-13